Dr. Solin on Personalizing Treatment With the DCIS Score

Lawrence J. Solin, MD
Published: Tuesday, Feb 28, 2012

Lawrence J. Solin, MD, chair, Department of Radiation Oncology, Einstein Medical Center, discusses a few of the differences between the Oncotype DX recurrence score and the new 12-gene assay for patients with ductal carcinoma in situ (DCIS), labeled the DCIS Score.

The DCIS Score, derived from the multigene RT-PCR assay, should be used for noninvasive DCIS tumors while the Oncotype DX test is primarily used for invasive tumors and carcinomas. Differences exist between the way the results of these tests are calculated and their impact on the treatment process.

Predicting the individual risk for local recurrence in patients with DCIS allows physicians to make personalized treatment decisions. Whether or not to provide radiation or tamoxifen can be aided by how the patient’s risk is categorized.

Lawrence J. Solin, MD, chair, Department of Radiation Oncology, Einstein Medical Center, discusses a few of the differences between the Oncotype DX recurrence score and the new 12-gene assay for patients with ductal carcinoma in situ (DCIS), labeled the DCIS Score.

The DCIS Score, derived from the multigene RT-PCR assay, should be used for noninvasive DCIS tumors while the Oncotype DX test is primarily used for invasive tumors and carcinomas. Differences exist between the way the results of these tests are calculated and their impact on the treatment process.

Predicting the individual risk for local recurrence in patients with DCIS allows physicians to make personalized treatment decisions. Whether or not to provide radiation or tamoxifen can be aided by how the patient’s risk is categorized.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x